TYK Medicines Inc. has patented compounds reported to be useful for the treatment of Alzheimer’s, Parkinson’s and Huntington diseases as well as amyotrophic lateral sclerosis, epilepsy and spinocerebellar ataxia.
Immunodesigners Co. Ltd. has discovered optical isomers of 2'-fluoro-6'-methylene carbocyclic adenosine monophosphate prodrug reported to be useful for the treatment of chronic hepatitis B.
Beijing Qinghui Liannuo Biotechnology Co. Ltd. has described compounds acting as butyrophilin subfamily 3 member A1 (BTN3A1) and 2A1 ligands reported to be useful for the treatment of cancer, autoimmune, inflammatory, cardiovascular disorders and infections.
Ajax Therapeutics Inc. has divulged tyrosine-protein kinase JAK2 inhibitors reported to be useful for the treatment of hematologic cancer (particularly, leukemia and lymphoma), myelofibrosis, polycythemia vera and essential thrombocythemia.
Insmed Inc. has identified cathepsin C (dipeptidyl peptidase I; DPP-1) inhibitors reported to be useful for the treatment of cancer, inflammatory bowel disease, bronchiectasis, asthma, cystic fibrosis, lupus nephritis, pulmonary hypertension and rheumatoid arthritis.
The proposal to overhaul the use of terminal disclaimers in U.S. patent filings won over no fans among former directors of the U.S. Patent and Trademark Office, but device and drug makers, too, are concerned about the proposal.
Kodiak Sciences Inc. has described NLRP3 inflammasome inhibitors reported to be useful for the treatment of age-related macular degeneration, choroidal neovascularization, diabetic macular edema, dry eye, glaucoma, bacterial keratitis, retinitis and uveitis, among others.
Apellis Pharmaceuticals Inc. has identified C3 convertase inhibitors reported to be useful for the treatment of cancer, obesity, infections, neurological disorders, autoimmune and inflammatory disorders, age-related macular degeneration and chronic obstructive pulmonary disease (COPD), among others.
RSS
